SCHEDULE 13D/A: Thomas Meyer Boosts Stake in Altamira Therapeutics, Now Holding 18.9% of Common Shares

Thomas Meyer, a significant shareholder, increased his beneficial ownership in Altamira Therapeutics Ltd. to 18.9% after receiving 1,053,392 common shares as a bonus.

Summary

• Thomas Meyer, the reporting person, filed Amendment No. 14 to his Schedule 13D regarding his beneficial ownership in Altamira Therapeutics Ltd.
• As of April 30, 2025, Mr. Meyer beneficially owns 1,079,843 Common Shares, representing 18.9% of the Issuer's outstanding Common Shares.
• This ownership includes 1,074,312 Common Shares and warrants/options to purchase up to 5,531 additional Common Shares exercisable within 60 days.
• The increase in ownership is primarily due to Mr. Meyer receiving 1,053,392 Common Shares on April 30, 2025, in lieu of a cash bonus, which was approved by the Issuer's Compensation Committee.
• The total outstanding Common Shares of Altamira Therapeutics Ltd. as of April 30, 2025, are 5,715,472.

Sentiment

Score: 6

Explanation: The document reports a routine update to beneficial ownership, primarily due to a share-based bonus. This is generally neutral to slightly positive as it aligns a key individual's interests with shareholders and conserves company cash, without indicating any negative operational or financial issues.

Positives

• Thomas Meyer received a significant share issuance (1,053,392 Common Shares) as a bonus, indicating continued compensation and alignment with shareholder interests.
• The issuance of shares in lieu of a cash bonus helps Altamira Therapeutics Ltd. conserve cash.
• Increased beneficial ownership by a key individual (Thomas Meyer now holds 18.9%) can signal confidence in the company's future.

Negatives

• The issuance of shares as a bonus could lead to minor dilution for existing shareholders, although the document does not specify the extent of dilution relative to the total outstanding shares before this event.

Future Outlook

The document does not provide specific forward-looking statements or guidance beyond the current beneficial ownership structure.

Management Comments

• The document notes that the share issuance to the Reporting Person was approved by the Compensation Committee of the Issuer.

Industry Context

This Schedule 13D filing is a routine disclosure of a change in beneficial ownership by a significant shareholder and does not provide broader industry context or trends.

Comparison to Industry Standards

• This document is a specific regulatory filing detailing a change in individual beneficial ownership and does not contain information suitable for comparison to global industry benchmarks, comparable companies, or projects.

Corporate Governance

Related Party Transactions

• Thomas Meyer, as the reporting person and a significant shareholder, received 1,053,392 common shares in lieu of a cash bonus, which constitutes a transaction with a related party (an insider).

Stakeholder Impact

• Shareholders: The issuance of shares as a bonus could lead to minor dilution, but it also aligns the interests of a significant shareholder (Thomas Meyer) with other shareholders and conserves company cash.
• Employees: The document does not provide information on impact to general employees.
• Customers/Suppliers/Creditors: The document does not provide information on impact to customers, suppliers, or creditors.

Key Dates

Recommendation

Keywords

Altamira Therapeutics, Thomas Meyer, Schedule 13D, Beneficial Ownership, Common Stock, Shareholder Stake, SEC Filing, Corporate Governance, Share Issuance, Compensation Committee